Every Form 4 that FibroGen, Inc (FGEN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FGEN filings page.
KYNTRA BIO, INC. CEO and director Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, increasing his direct holdings to 27,203 shares. A separate line shows 40 shares of common stock held indirectly through his spouse.
KYNTRA BIO, INC. CEO Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, bringing his direct holdings to 27,203 shares. He also reports indirect ownership of 40 shares held by his spouse.
KYNTRA BIO, INC. CEO and director Thane Wettig reported a routine tax-related share disposition. On March 6, 2026, 277 shares of common stock were withheld by the issuer at $6.84 per share to satisfy taxes due upon the vesting of restricted stock units. After this withholding, Wettig held 24,403 common shares directly, and an additional 40 shares were held indirectly by his spouse.
KYNTRA BIO, INC. Chief Financial Officer David DeLucia reported a small tax-related share disposition. On the vesting of restricted stock units, 60 shares of common stock were withheld by the company to cover his tax obligations. After this withholding, he directly owns 4,429 common shares.
This was a tax-withholding disposition, not an open-market sale or purchase, so it mainly reflects routine equity compensation mechanics rather than a change in his investment view on the company.
Kyntra Bio, Inc. reported that CEO and director Thane Wettig received a grant of stock options. On February 3, 2026, he was awarded options to purchase 60,000 shares of common stock at an exercise price of $8.50 per share, with no cash price paid for the grant itself.
The options vest in equal amounts quarterly over four years starting from February 3, 2026, and are exercisable until February 2, 2036. Following this award, Wettig beneficially owns 60,000 stock options, held directly.
Kyntra Bio, Inc. reported an option grant to its Chief Financial Officer, David DeLucia. On 02/03/2026, he was awarded a stock option for 26,000 shares of common stock at an exercise price of $8.50 per share.
The option vests in equal amounts quarterly over four years starting on 02/03/2026. Following this grant, DeLucia beneficially owns 26,000 derivative securities directly through this option award.
FibroGen, Inc. (FGEN) reported insider buying by its Chief Executive Officer and Director in a Form 4 filing. On 11/13/2025, the reporting person purchased 1,000 shares of common stock at $9.18 per share. On 11/17/2025, an additional 2,700 shares were purchased at $9.0999 per share. After these transactions, the reporting person beneficially owned 24,939 shares of FibroGen common stock directly and 40 shares indirectly through a spouse. The filing was made by a single reporting person in the roles of both CEO and Director.